-DOCSTART- -X- O
Infectious -X- _ O
complications -X- _ O
, -X- _ O
particularly -X- _ O
in -X- _ O
the -X- _ O
respiratory -X- _ B-Patient
tract -X- _ I-Patient
of -X- _ I-Patient
critically -X- _ I-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
, -X- _ O
are -X- _ O
related -X- _ B-Outcome
to -X- _ I-Outcome
increased -X- _ I-Outcome
mortality. -X- _ I-Outcome
Severe -X- _ O
infection -X- _ O
is -X- _ O
part -X- _ O
of -X- _ O
a -X- _ O
multiple -X- _ O
system -X- _ O
illness -X- _ O
and -X- _ O
female -X- _ B-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
sepsis -X- _ I-Outcome
have -X- _ I-Outcome
a -X- _ I-Outcome
worse -X- _ I-Outcome
prognosis -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
males. -X- _ I-Outcome
Kallistatin -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
protective -X- _ I-Outcome
hormokine -X- _ I-Outcome
released -X- _ I-Outcome
during -X- _ I-Outcome
monocyte -X- _ I-Outcome
activation -X- _ I-Outcome
and -X- _ I-Outcome
low -X- _ I-Outcome
levels -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
setting -X- _ I-Outcome
of -X- _ I-Outcome
septic -X- _ I-Outcome
shock -X- _ I-Outcome
can -X- _ I-Outcome
predict -X- _ I-Outcome
adverse -X- _ I-Outcome
outcomes. -X- _ I-Outcome
Presepsin -X- _ I-Outcome
is -X- _ I-Outcome
another -X- _ I-Outcome
biomarker -X- _ I-Outcome
that -X- _ I-Outcome
was -X- _ I-Outcome
recently -X- _ I-Outcome
evaluated -X- _ I-Outcome
and -X- _ I-Outcome
is -X- _ I-Outcome
elevated -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
severe -X- _ I-Outcome
sepsis -X- _ I-Outcome
patients -X- _ I-Outcome
at -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
dying. -X- _ I-Outcome
The -X- _ O
Centers -X- _ O
for -X- _ O
Disease -X- _ O
Control -X- _ O
and -X- _ O
Prevention -X- _ O
has -X- _ O
introduced -X- _ O
new -X- _ O
definitions -X- _ O
for -X- _ O
identifying -X- _ O
patients -X- _ O
at -X- _ O
risk -X- _ O
of -X- _ O
ventilator-associated -X- _ O
complications -X- _ O
( -X- _ O
VACs -X- _ O
) -X- _ O
, -X- _ O
but -X- _ O
several -X- _ O
other -X- _ O
conditions -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
pulmonary -X- _ O
edema -X- _ O
and -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome -X- _ O
, -X- _ O
may -X- _ O
cause -X- _ O
VACs -X- _ O
, -X- _ O
and -X- _ O
not -X- _ O
all -X- _ O
patients -X- _ O
with -X- _ O
VACs -X- _ O
may -X- _ O
have -X- _ O
ventilator-associated -X- _ O
pneumonia. -X- _ O
New -X- _ O
studies -X- _ O
have -X- _ O
suggested -X- _ O
strategies -X- _ O
to -X- _ O
identify -X- _ O
patients -X- _ O
at -X- _ O
risk -X- _ O
for -X- _ O
resistant -X- _ O
pathogen -X- _ O
infection -X- _ O
and -X- _ O
therapies -X- _ O
that -X- _ O
optimize -X- _ O
efficacy -X- _ O
, -X- _ O
without -X- _ O
the -X- _ O
overuse -X- _ O
of -X- _ O
broad-spectrum -X- _ O
therapy -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
healthcare-associated -X- _ O
pneumonia. -X- _ O
Innovative -X- _ O
strategies -X- _ O
using -X- _ O
optimized -X- _ O
dosing -X- _ O
of -X- _ O
antimicrobials -X- _ O
, -X- _ O
maximizing -X- _ O
the -X- _ O
pharmacokinetic -X- _ O
and -X- _ O
pharmacodynamic -X- _ O
properties -X- _ O
of -X- _ O
drugs -X- _ O
in -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
, -X- _ O
and -X- _ O
newer -X- _ O
routes -X- _ O
of -X- _ O
drug -X- _ O
delivery -X- _ O
are -X- _ O
being -X- _ O
explored -X- _ O
to -X- _ O
combat -X- _ O
drug-resistant -X- _ O
pathogens. -X- _ O
We -X- _ O
summarize -X- _ O
the -X- _ O
major -X- _ O
clinical -X- _ O
studies -X- _ O
on -X- _ O
respiratory -X- _ B-Patient
infections -X- _ I-Patient
in -X- _ I-Patient
critically -X- _ I-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
published -X- _ O
in -X- _ O
2013 -X- _ O
. -X- _ O

